Companies › CeleCor Therapeutics
1 active drug program in 1 registered trial: 1 Phase 3; Cardiovascular.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Zalunfiban Integrin alpha-IIb/beta-3 inhibitor | ITGB3, ITGA2B | Phase 3 | ST-elevation Myocardial Infarction (STEMI) | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT04825743 | Zalunfiban | Phase 3 | ST-elevation Myocardial Infarction (STEMI) | Cardiovascular | May 2026 |
–
MedTrace Pharma SPH Qingdao Growful Pharmacetical Hanlim Pharm. Trust Bio-sonics Liquidia Technologies
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.